Obesity and its associated pathology Type 2 diabetes are two chronic metabolic and inflammatory diseases that promote breast cancer progression, metastasis, and poor outcomes. Emerging critical opinion considers unresolved inflammation and abnormal metabolism separately from obesity; settings where they do not co-occur can inform disease mechanism. In breast cancer, the tumor microenvironment is often infiltrated with T effector and T regulatory cells programmed by metabolic signaling. The pathways by which tumor cells evade immune surveillance, immune therapies, and take advantage of antitumor immunity are poorly understood, but likely depend on metabolic inflammation in the microenvironment. Immune functions are abnormal in metabolic disease, and lessons learned from preclinical studies in lean and metabolically normal environments may not translate to patients with obesity and metabolic disease. This problem is made more urgent by the rising incidence of breast cancer among women who are not obese but who have metabolic disease and associated inflammation, a phenotype common in Asia. The somatic BET proteins, comprising BRD2, BRD3, and BRD4, are new critical regulators of metabolism, coactivate transcription of genes that encode proinflammatory cytokines in immune cell subsets infiltrating the microenvironment, and could be important targets in breast cancer immunotherapy.
low-level inflammation, arising locally in part from these infiltrating immune cells that contact the adipocytes of the fat depot. Exposure of adipocytes and muscle cells to proinflammatory cytokines was shown to directly cause (not "associate with") insulin resistance. 8, 9 Chronic, systemic imbalances in proinflammatory and anti-inflammatory cytokines also characterize metabolic abnormalities such as Type 2 diabetes (T2D) and are critical for disease pathogenesis. [10] [11] [12] [13] [14] BET proteins also critically regulate transcription of many cytokine genes.
Given the preponderance of evidence directly linking metabolic inflammation to cancer initiation and progression, molecular and cellular models of insulin-resistant obesity are being explored to understand mechanisms that drive risks for cancer incidence and progression in obesity. These studies will undoubtedly build on observations made in population studies when obesity was first recognized as an inflammatory disease. [15] [16] [17] Furthermore, new molecular insights are revealing how stromal, nonmalignant cells of the tumor microenvironment, particularly immune infiltrates and adipocytes, where BET proteins are also crucial for function, are abnormal in T2D and drive tumor promotion and metastasis. [18] [19] [20] Here, we will discuss how the BET proteins are critical players in breast cancer progression, 21 as well as in abnormal function of the stromal cells of the tumor microenvironment.
BET PROTEINS IN CANCER
Histone acetylases and deacetylases are critical to control condensation of chromatin, adding acetyl groups to specific peptides of nucleosomal histones that permit recruitment of coactivators to the target genes. These acetyl groups are "read" by the bromodomain motif, 22 comprised of four, bundled, antiparallel -helices connected by two loops. 23 The loops bind to the acetyl groups of the histones with nanomolar affinity constants. The motif is found in an estimated 42 human proteins 24 and is highly conserved across eukaryotes. 25 This 110-amino acid structure occurs in the BET family as two tandem, mutually related bromodomains at the amino terminal end of the polypeptide, accompanied by an "extraterminal" protein interaction domain that is always positioned carboxyl-terminal to the dual bromodomains. 26, 27 The BET family is comprised of three somatic proteins BRD2, BRD3, and BRD4, and a testis-specific form BRDT. 24 Enzyme or coactivator functions that are part of a polypeptide containing the bromodomain are thereby recruited to chromatin to change transcriptional activity. 28, 29 Thus, an individual BET protein can bind to acetylated histones at promoter chromatin through its bromodomains, and through its extraterminal domain or other carboxyl terminal domain. The BET protein can then recruit coactivators/histone acetylases to up-regulate transcription of the target gene or corepressors/histone deacetylases to down-regulate transcription of the target gene in a versatile fashion. [30] [31] [32] [33] In addition to epigenetic types of regulation through histone-modifying enzymes, these recruited proteins include transcription factors critical for cell cycle gene regulation and mitosis, such as E2F proteins, 30, 32, 34 p53 and Myc 35 or P-TEFb 36,37 ; or also central for epithelial-to-mesenchymal transition (EMT), such as Twist 38 ; or inflammation, such as NF-B. 39 BET proteins have long been known as drivers of human cancer, 40 sometimes through mutation but more commonly through overexpression. Specific, reproducible and reciprocal translocations of chromosomes that break the BRD3 and BRD4 genes drive aggressive carcinomas of the midline in humans. 41 BRD4 function in particular has been implicated in mitotic control, [42] [43] [44] [45] BRD2 in cyclin gene transcription 46 and BRD3 in GATA1 transcription. 47, 48 Mistargeting of chromatin regulators and transcription-modifying enzymes 30, 31, 49 through chromosomal translocation is likely an essential step in this type of oncogenic transformation, which leads to deregulation of genes like cyclin D1 that are important for breast cancer. 50 The discovery of small molecule "pan-BET" inhibitors (BETi), such as JQ1 51 and I-BET, 39 which displace all BET proteins from promoter chromatin at low nanomolar concentrations, has generated significant excitement.
Chromatin is now demonstrated to be "druggable" 52 and epigenetic therapeutics for diverse cancers may be possible. 53 The roles of BET bromodomain proteins and the potential utility of pan-BETi in diverse cancers have been well reported, including for myeloma, 54 lymphoma and leukemia, [55] [56] [57] [58] neuroblastoma, 59 prostate, 60 lung, 61 and other tumor types.
In human breast cancer subtypes, several epigenetic factors are overexpressed 62, 63 and inhibition of BET proteins shows promise. 64 In some studies, triple negative cell lines show sensitivity to panBETi, blocking proliferation and promoting apoptosis. 65 Unfortunately, those experiments were conducted at physiologically irrelevant concentrations (2-20 M) and did not discriminate among BRD2, BRD3, and BRD4, which have overlapping and sometimes opposing functions. 53 Interestingly, estrogen receptor (ER) -positive breast cancer that is resistant to tamoxifen may be amenable to BETi approaches, by blocking recruitment of the histone H3K36 methyltransferase WHSC1, which regulates ER transcription and is overexpressed in certain poor-prognosis breast tumors. 66 This mechanism appears to involve BRD3 and BRD4 but not BRD2. New results also show that BRD4 controls invasion and migration behaviors of several types of breast cancer. 67 The mechanisms of BET protein misregulation that contribute to obesity-associated breast cancer are an emerging focus of investigation. 68 
BET PROTEINS IN METABOLIC INFLAMMATION AND BREAST CANCER IN OBESITY
DNA-binding transcription factors are essential for regulation of genes that control production of inflammatory cytokines, such as NF-B, and of genes that control adipocyte differentiation, such as peroxisome proliferator-activated receptor gamma (PPAR ). In addition to cis-acting transcription factors, these genes also require epigenetic regulators that modify chromatin and enable RNA polymerase access to promoters; these regulators include the BET proteins. In Tumor cells engage in paracrine signal transduction networks with nearby white adipocytes and proinflammatory T cell subsets that infiltrate the adipose tissue depot. The functions of these nontumor cell types are highly abnormal in T2D and likely drive tumor progression. BET bromodomain proteins regulate tumor cell proliferation, invasiveness, migration, and metastatic potential in response to these signals from the microenvironment cells, as well as immune exhaustion markers (e.g., PD-L1) that are elevated in metabolic inflammation. These nontumor cells both up-regulate immune exhaustion markers on lymphocytes (e.g., PD-1) in response to metabolic inflammation, 144 and produce cytokines, under the control of the same subset of BET bromodomain proteins. Therefore, small molecule inhibitors that selectively ablate production of prometastatic factors could reduce the risks for tumor progression, improve immune exhaustion in metabolic disease, and "cure" the microenvironment, as well as reduce tumor proliferation and cell-intrinsic metastatic programs like EMT Small molecule approaches must therefore be sufficiently selective to carefully avoid undesirable on-target effects in nearby nontumor cells of the microenvironment or elsewhere in the patient. 53 Ac, acetyl groups; Pol II, RNA Polymerase II; TAF, TATA-binding protein-associated factor Brd2 increases insulin transcription, likely through transcriptional derepression 71 in both cell lines and animal models, 72 and improves -cell metabolism, 73 while reduced expression of BRD4 also increases -cell insulin content. 73 BET proteins are functionally critical for inflammation and adipogenesis. Here, we focus on two stromal cell types in the breast tumor microenvironment that are crucial in T2D: T cell subsets and white adipocytes (Fig. 1) . BET proteins interact with both NF-B 74 and PPAR 71 in ternary complexes 75 and can coactivate or corepress target genes, depending on the enzymatic activities in the ternary complex. [30] [31] [32] [33] [34] T2D, a chronic inflammatory disease, increases risk of breast cancer incidence 81 and mortality. 82 Inflammation also contributes to breast cancer aggressiveness and metastasis. 83 It is likely that the increased breast cancer risk in postmenopausal women with T2D is exacerbated by inflammatory processes. In obesity-driven T2D, adipose tissue produces proinflammatory cytokines and adipokines that alter the breast tumor microenvironment, increasing progression of invasive, metastatic cancer. Specifically, the inflammatory status of breast adipose tissue is positively correlated with tumor aggressiveness. [18] [19] [20] 84 Furthermore, "metabolically healthy" adults, who show less local and systemic inflammation 85 than obese adults with comorbid T2D and hypertension, have reduced incidence of certain cancers. 86 [100] [101] [102] [103] are also deregulated in T2D and are important for tumor cell migration, invasion, survival, and proliferation. [104] [105] [106] [107] [108] The genes that encode many of these cytokines and chemokines are also positively regulated by one or more BET proteins. [109] [110] [111] These reports suggest that new, small molecule BETi can also improve the inflammatory microenvironment for therapeutic benefit, especially in patients with T2D and other chronic inflammatory diseases that are comorbid with their cancers. Given the potent anti-inflammatory action of BETi, through their effects on transcription of NF-B target genes 39, 74 and STAT target genes, 112 these approaches represent potentially effective avenues for intervention in inflammation and metastasis in breast cancer.
METABOLIC INFLAMMATION AND BREAST CANCER WITHOUT OBESITY
New research is forcing consideration of the disturbing possibility that "obesity-associated" breast cancer is rising worldwide in women who are not apparently obese. Within the last year, work has shown that certain lean women show elevated biomarkers of inflammation both systemically and locally in breast adipose tissue, which associate with increased aromatase and breast cancer risk. 113, 114 These insights provoke a radical hypothesis: obesity per se is less important for cancer risk than metabolic inflammation, which need not accompany expanded fat depots or elevated body mass at all. This hypothesis represents a major paradigm shift, because previous research in obesity-associated cancers has tended to focus wholly on obesity itself, rather than the abnormal metabolism and inflammation that often accompany obesity. 115 Two well-established drivers of breast cancer progression, leptin, adiponectin (and their ratio), are deregulated in obesity, but generally are not abnormal in lean women, although they are abnormal in metabolic disease. 116 These transformations are taking place against a background of evolutionary pressure that selected for human populations with high insulin sensitivity and superb ability to store or metabolize glucose.
A severe metabolic imbalance has quickly emerged in Asia over the last fifteen years. As economies have improved, the calorie-activity equilibrium of centuries has been upset. This well described economic change now drives a major shift in incidence patterns for cardiometabolic disease. 119 Macroeconomic forces such as urbanization and rising incomes are increasing sedentary behavior 120 and stimulating consumption of high-glycemic index foods, which together promote T2D. The relative impact of infectious diseases is decreasing, whereas chronic inflammatory conditions like T2D increasingly dominate the disease patterns in these regions. 121 Furthermore, unlike Europeanorigin or African-origin adults, fat deposition in South Asians, Koreans, Chinese, and other Pacific groups of people is not necessarily into discrete depots, but internally and "ectopically" into visceral organs like liver, kidney, and heart. Such a distribution is long known to endocrinologists as the "metabolically obese normal weight" phenotype. 122, 123 Such adults need not reach high body weights to experience dangerous risks for T2D. Throughout the Asia-Pacific region, T2D and metabolic inflammation is rising quickly among adults who are underweight, lean, normal weight, and slightly overweight. 124 With respect to breast cancer in India, incidence has been rising rapidly among younger women, and population-based cancer registries show significant increases in age-adjusted incidence rates for breast cancer from 2011 to 2014. 125 Breast cancers in these younger patients also tend to take more aggressive forms. Several problems concern this emerging field. Different kinds of obesity carry different cancer risks. 86, 87 Whether T2D in obesity and T2D in lean women is the same disease with respect to breast cancer incidence and progression is yet to be explored. More broadly, it is not yet possible to leverage our current knowledge of metabolic inflammation to understand cancer progression in different types of patients. Emerging critical opinion 126 recognizes that the same subtype of cancer behaves quite differently depending on whether the patient is lean and metabolically normal, obese and diabetic, or lean and diabetic. In each case, the nature of T2D-associated inflammatory cytokines and cellular infiltrates likely makes a critical difference. New thinking will be required to address this emerging crisis of breast cancer driven by metabolic disease and chronic inflammation, but in patients who are relatively lean, about whom little is known. 
BET PROTEINS AND METFORMIN IN BREAST CANCER
One of the most successful and inexpensive treatments for T2D in obesity has been metformin (1,1-dimethylbiguanide), which has long been used effectively in the clinic. Metformin inhibits the mitochondrial complex I in diverse tissues, 127 Thus, rapid AMPK activation after matrix detachment 136 can serve as an adaptable switch to alter cellular metabolism 137 and promote tumor cell survival in the circulation. 138 Furthermore, high grade breast cancers show elevated AMPK activation 136 and are associated with hypoxia, which both drives EMT 139 and activates AMPK. 140 Ongoing research strongly supports a role for AMPK in promoting EMT downstream of several stimuli. These processes are protumorigenic, suggesting a troubling possibility that metformin treatment may have undesirable, prometastatic side effects for certain breast cancer patients. where it is associated with poor prognosis, 146 and is also elevated in patients with T2D. 144 Moreover, chronic antigen exposure in cancer can lead to persistent high-level PD-1 expression on antigenexperienced T cells, impairing effector function and up-regulating inhibitory receptors, termed "T cell exhaustion". 147 PD-L1 expression is associated with poor prognosis and fewer TILs in several cancer types. Cancer cell-induced activation of this pathway might also explain why, in ongoing studies that investigate cancer vaccination, there is no tumor growth control despite the induction of cancerspecific T cells. 148 These observations provide a strong rationale to target PD-1 or its ligand PD-L1 with antibodies capable of inhibiting this pathway, an approach that has already shown promise for triple negative breast cancer. 149 BET proteins (Fig. 1) are newly implicated in the expression of PD-L1 in ovarian cancer 150 and B cell lymphoma. 151 New approaches that target family members individually will reveal mechanisms that are obscured by pan-BETi, 53 and could then be leveraged with checkpoint inhibitors in innovative combinations. Thus, a new therapeutic opportunity has arisen to exploit BETi in immunotherapy.
BET PROTEINS IN METABOLIC INFLAMMATION AND IMMUNE EXHAUSTION
As discussed above, the breast tumor microenvironment is char- Evidence supports a mechanism for metformin treatment in T2D
to improve PD-1 exhaustion. 153 Based on these considerations, it is reasonable to hypothesize that BET proteins regulate PD-1 expression in T cells in the breast tumor microenvironment. In recently published work, we showed that BRD4, but not BRD2 or BRD3, is critical for Notch1 signaling activation in a triple negative breast cancer model. 67 Thus, we hypothesize that Notch1-mediated PD-1 expression 154 is critically dependent on BET proteins, likely BRD4.
Moreover, as described above, BET proteins are crucial regulators of proinflammatory cytokines production and signaling. Therefore, we expect to find that BET inhibition in activated T cells prevents inflammatory cytokine-driven PD-1 expression in the breast tumor microenvironment. These insights will be important to explore in breast cancer patients with comorbid T2D.
CONCLUSIONS
BET proteins are likely to play important roles in metabolic inflamma- 
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